330 related articles for article (PubMed ID: 26667821)
1. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
2. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
[TBL] [Abstract][Full Text] [Related]
3. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
[No Abstract] [Full Text] [Related]
4. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
5. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
6. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
[TBL] [Abstract][Full Text] [Related]
7. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
[TBL] [Abstract][Full Text] [Related]
8. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
9. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
[TBL] [Abstract][Full Text] [Related]
10. Quercetin sensitizes pancreatic cancer cells to TRAIL-induced apoptosis through JNK-mediated cFLIP turnover.
Kim JH; Kim MJ; Choi KC; Son J
Int J Biochem Cell Biol; 2016 Sep; 78():327-334. PubMed ID: 27477310
[TBL] [Abstract][Full Text] [Related]
11. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Yerbes R; López-Rivas A
Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
13. Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines.
Park EJ; Kim HD; Choi EK; Hoe KL; Kim DU
Biochem Biophys Res Commun; 2020 Dec; 533(3):289-295. PubMed ID: 32958259
[TBL] [Abstract][Full Text] [Related]
14. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.
Murtaza I; Saleem M; Adhami VM; Hafeez BB; Mukhtar H
Cancer Res; 2009 Feb; 69(3):1156-65. PubMed ID: 19176377
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.
Clarke P; Tyler KL
Apoptosis; 2007 Jan; 12(1):211-23. PubMed ID: 17136319
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
17. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents.
Sánchez-Pérez T; Ortiz-Ferrón G; López-Rivas A
Cell Death Differ; 2010 May; 17(5):883-94. PubMed ID: 19942932
[TBL] [Abstract][Full Text] [Related]
18. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
19. ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis.
Stagni V; Mingardi M; Santini S; Giaccari D; Barilà D
Carcinogenesis; 2010 Nov; 31(11):1956-63. PubMed ID: 20876284
[TBL] [Abstract][Full Text] [Related]
20. Icariside II overcomes TRAIL resistance of melanoma cells through ROS-mediated downregulation of STAT3/cFLIP signaling.
Du J; Wu J; Fu X; Tse AK; Li T; Su T; Yu ZL
Oncotarget; 2016 Aug; 7(32):52218-52229. PubMed ID: 27418138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
